Atlas Trials

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

Clinical trial NCT02919501 · COMPLETED

Trial details

NCT number
NCT02919501
Sponsor
H. Lundbeck A/S
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Depressive Disorder, Major
Start date
2016-09-27
Primary completion
2017-04-27
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.